Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT07219511 is registered in ClinicalTrials.gov with Vasa Therapeutics as lead sponsor.

NCT NCT07219511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Lead sponsor
Vasa Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
November 4, 2025
Completion date
July 31, 2026
Enrollment
42 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

heart, heart failure with preserved ejection fraction (hfpef)